Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olverembatinib Plus Venetoclax and Dexamethasone in Newly-diagnosed Ph+ ALL
NCT06082934Phase 2Recruiting
- Sponsor
- Xijing Hospital
- Start
- Nov 2023
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olverembatinib in acute lymphoblastic leukemia (ALL), sponsored by Xijing Hospital. Started Nov 2023; status: recruiting.
02
Drugs
olverembatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06082934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06082934.